Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 11 de 11
Filter
1.
Braz J Infect Dis ; 5(2): 50-2, 2001 Apr.
Article in English | MEDLINE | ID: mdl-11493408

ABSTRACT

In recent years, the level of resistance of S. pneumoniae to beta-lactam and/or macrolides has increased around the world including some countries in South America. Because of this resistance, it is necessary to test the therapeutic alternatives for treating this pathogen, including the newer quinolones. This study was carried out in order to compare the in vitro activity of fluoroquinolones gatifloxacin, levofloxacin and trovafloxacin, to penicillin G, amoxicillin, amoxicillin-clavulanate, cufuroxime sodium, ceftriaxone, azithromycin and clarithromycin, against 300 strains of S. pneumoniae. Of the 300 samples tested, 18.6% were not susceptible to penicillin (56 strains) and 7% (21 strains) were resistant to the second generation cephalosporin. Among the macrolides, resistance ranged from 6.7% for clarithromycin to 29.6% for azithromycin. Susceptibility to the newer quinolones was 100% including the 56 strains not susceptible to penicillin. Among the 10 antibiotics evaluated, the fluoroquinolones gatifloxacin, levofloxacin, and trovafloxacin displayed high levels of in vitro activity against S. pneumoniae.


Subject(s)
Anti-Bacterial Agents/pharmacology , Anti-Infective Agents/pharmacology , Fluoroquinolones , Streptococcus pneumoniae/drug effects , Drug Resistance, Microbial , Drug Resistance, Multiple , Gatifloxacin , Levofloxacin , Macrolides , Microbial Sensitivity Tests , Naphthyridines/pharmacology , Ofloxacin/pharmacology , Pneumococcal Infections/drug therapy
2.
Braz J Infect Dis ; 5(1): 8-12, 2001 Feb.
Article in English | MEDLINE | ID: mdl-11290309

ABSTRACT

Surveillance programs are essential to detect the increase of antimicrobial resistance, and several different programs are being conducted in many countries. The RESISTNET is a surveillance program for bacterial resistance against several antimicrobial agents initiated in 1998 among Latin American countries. In Brazil, several centers were invited to join this surveillance and a total of 11 centers (6 from São Paulo and 5 from other states) participated in the study. All results were analyzed using the WHONET program. A total of 894 Escherichia coli, 386 Klebsiella pneumoniae, 70 Shigella spp and 57 Salmonella spp strains were analyzed in this study from April, 1998, to April, 1999. Susceptibility testing was performed by the disk diffusion method using NCCLS 1998 guidelines for several different drugs. For all strains, imipenem was the most effective drug (100% of the strains were susceptible). Klebsiella pneumoniae presented a high resistance rate to ampicillin (96.4%). The rate of probable ESBL producers among K. pneumoniae strains was 36.3%, most of them being isolated from catheters (58.8%). Among all Escherichia coli strains analyzed, the highest resistance rate was found for trimethoprim/sulfamethoxazole (46.9%) and the majority of the resistant strains were isolated from urine samples (47.8%). Among Salmonella spp, the resistance rates were low for all antibiotics tested. For Shigella spp strains there was a high resistance to trimethoprim/sulfamethoxazole (80.0%). No resistance to ceftriaxone was observed in these strains. Surveillance of antimicrobial resistance is critical for the successful management of infectious diseases. The results of this survey show significant resistance rates among these bacteria which are responsible for several types of human infections.


Subject(s)
Anti-Bacterial Agents/pharmacology , Escherichia coli/drug effects , Klebsiella pneumoniae/drug effects , Salmonella/drug effects , Shigella/drug effects , Brazil , Drug Resistance, Microbial , Microbial Sensitivity Tests
3.
Braz J Infect Dis ; 5(5): 252-9, 2001 Oct.
Article in English | MEDLINE | ID: mdl-11779451

ABSTRACT

This study was done to determine the occurrence of mycobacteria in the bloodstreams of patients with fever and advanced AIDS in a Brazilian hospital. We also verified the capability of an automated method for recovering these bacteria. During a period of 19 months, 254 patients with AIDS were evaluated. Blood cultures were generally submitted in pairs and drawn separately. Blood cultures were processed by the BACTEC 460TB System (Becton Dickinson Microbiology Systems, Sparks, MD), using the Bactec 13A media (Becton Dickinson Microbiology Systems, Sparks, MD). Of the 530 vials submitted, 77 (14.5%) from 41 (16%) patients were positive. Mycobacterium avium complex was recovered from 45 (58.4%) of the 77 positive vials, corresponding to 22 (53.6%) patients with positive blood cultures. The average time to detect Mycobacterium avium complex was 15 days. Mycobacterium tuberculosis was recovered from 26 (33.8%) of the 77 positive vials, corresponding to 15 (36.6%) patients with positive blood cultures, with an average detection time of 24 days. Other species of mycobacteria were recovered from 6 (7.8%) of the 77 vials, corresponding to 4 (9.8%) patients. M.avium complex was fairly prevalent (8.7%) in severely ill patients with AIDS in our hospital. M. tuberculosis was also an important (6.0%) agent of systemic bacterial infections in these patients. The rapid diagnosis of mycobacteremia was possible with the implementation of this automated technology.


Subject(s)
AIDS-Related Opportunistic Infections/diagnosis , AIDS-Related Opportunistic Infections/microbiology , Bacteremia/microbiology , Mycobacterium avium Complex/isolation & purification , Mycobacterium avium-intracellulare Infection/diagnosis , Mycobacterium tuberculosis/isolation & purification , Tuberculosis/diagnosis , Bacteremia/etiology , Brazil , Hospitals, University , Humans , Mycobacterium avium-intracellulare Infection/etiology , Tuberculosis/etiology
4.
Braz J Infect Dis ; 5(5): 269-76, 2001 Oct.
Article in English | MEDLINE | ID: mdl-11779453

ABSTRACT

This study was conducted to evaluate the activity of azithromycin in comparison to 12 other antibacterial agents against recent isolates obtained consecutively from patients with respiratory tract or skin infections, from January to July, 2000. A total of 717 Gram-positive cocci were analyzed in this study and the following species were studied: Staphylococcus aureus (n=576), beta-hemolytic streptococci (n=115), and Streptococcus pneumoniae (n=26). Susceptibility testing was carried out by the disk diffusion method and interpreted according to NCCLS breakpoints. The activity of azithromycin was compared to erythromycin, clindamycin, chloramphenicol, ciprofloxacin, ofloxacin, oxacillin, penicillin, ceftriaxone, tetracycline, trimethoprim/sulfamethoxazole, teicoplanin, and vancomycin. Of the 26 S. pneumoniae isolates recovered from the respiratory tract, 5 (19.2%) were intermediate resistant to penicillin. All of these strains were susceptible to chloramphenicol, ofloxacin, and vancomycin, and 24 (92%) were also susceptible to azithromycin, clindamycin, and erythromycin. Among the 67 beta-hemolytic streptococci strains isolated from the respiratory tract, 66 (99%) were susceptible to azithromycin, erythromycin, clindamycin, and ofloxacin. All 48 beta-hemolytic streptococci strains isolated from skin were susceptible to azithromycin and clindamycin, 47 (98%) were susceptible to erythromycin, and 46 (96%) were susceptible to ofloxacin. Of the 576 strains of S. aureus, 253 (43.9%) were isolated from the respiratory tract and 323 (56.1%) from skin. Among S. aureus isolates from the respiratory tract and skin, 46 (18%) and 78 (24%), respectively were resistant to oxacillin. Isolates from the respiratory tract and skin showed the same percentage of resistance (36%) to azithromycin. These in vitro results suggest that azithromycin can be a therapeutic option for treatment of infections caused by these bacteria since the newer macrolides have several distinct advantages over erytromycin including improved oral bioavailability, longer half-life allowing once or twice daily administration, higher tissue concentrations and less gastrointestinal adverse effects.


Subject(s)
Anti-Bacterial Agents/pharmacology , Azithromycin/pharmacology , Gram-Positive Cocci/drug effects , Respiratory System/microbiology , Skin/microbiology , Gram-Positive Cocci/isolation & purification , Humans , In Vitro Techniques , Microbial Sensitivity Tests , Staphylococcus aureus/drug effects , Streptococcus pneumoniae/drug effects
5.
Braz J Infect Dis ; 4(5): 236-44, 2000 Oct.
Article in English | MEDLINE | ID: mdl-11063555

ABSTRACT

Multi-resistant bacterial strains are increasingly prevalent in hospital environments. Bacterial resistance is an important problem, especially for practitioners in intensive care units (ICUs) because of the selective pressure on the prevalent bacteria in these environments. The MYSTIC (Meropenem Yearly Susceptibility Test Information Collection) study has been monitoring the performance of carbapenems and other antibiotics in different hospitals for at least 3 years. The in vitro activities of meropenem, imipenem, ceftazidime, cefepime, cefotaxime, ciprofloxacin, piperacilin/tazobactam, gentamicin, and tobramycin were compared against 452 recent clinical aerobic isolates. The isolates consisted of 19 species of Gram-negative bacteria (n=290) including K. pneumoniae (n=49), E. coli (n=48), A. baumannii (n=47), Enterobacter spp. (n=41), and P. aeruginosa (n=33) and 9 species of Gram-positive bacteria (n=162) including Staphylococcus aureus (n=63), Enterococcus faecalis (n=22), Streptococcus pneumoniae (n=22) and coagulase negative Staphylococci (n=21). All isolates were collected from ICU patients. Minimal inhibitory concentrations (MICs) were determined by Etest methodology, using standardized and controlled procedures. Meropenem and imipenem showed the lowest MIC(90) for all species tested. Gram-negative isolates showed the following overall resistance percentages to the other 7 drugs: tobramycin (43.1%), cefotaxime (38.6%), gentamicin (34.1%), ceftazidime (31.7%), ciprofloxacin (25.5%), piperacillin/tazobactam (26.9%), and cefepime (18.6%). Carbapenems were the most active drugs overall and only P. aeruginosa presented some degree of resistance (18.2%). We also evaluated the production of extended spectrum beta-lactamase (ESBL) among all Enterobacteriaceae members (n=176) by Etest/ESBL strip. ESBL production was detected in 51 strains (29.0%). Among them, Klebsiella pneumoniae was the most prevalent at 59.2%, followed by Enterobacter spp. (19.5%) and E. coli (14.6%). The high level of resistance against several antimicrobials and the alarming rate of ESBL production may restrict therapeutic choice to the carbapenems in this selected group of patients.


Subject(s)
Anti-Bacterial Agents/pharmacology , Bacteria/drug effects , Cross Infection/microbiology , Intensive Care Units , Lactams/pharmacology , Bacteria/isolation & purification , Bacterial Infections/microbiology , Brazil , Carbapenems/pharmacology , Drug Resistance, Microbial , Drug Resistance, Multiple , Humans , Microbial Sensitivity Tests/methods , Sentinel Surveillance
6.
Infect Control Hosp Epidemiol ; 20(9): 620-3, 1999 Sep.
Article in English | MEDLINE | ID: mdl-10501262

ABSTRACT

A case-control study was done to evaluate factors associated with nosocomial infections by multiresistant Pseudomonas aeruginosa (MRPA). Results showed that MRPA was associated with the use of immunosuppressive and antimicrobial drugs. Five typing methods indicated that the MRPA infections were due to multiple strains rather than a single strain.


Subject(s)
Anti-Bacterial Agents/therapeutic use , Cross Infection/classification , Cross Infection/epidemiology , Drug Resistance, Multiple , Pseudomonas Infections/classification , Pseudomonas Infections/epidemiology , Pseudomonas aeruginosa/drug effects , APACHE , Adult , Aminoglycosides , Bacteriophage Typing , Brazil/epidemiology , Case-Control Studies , Cross Infection/microbiology , Female , Humans , Infection Control , Male , Middle Aged , Pseudomonas aeruginosa/classification , Pseudomonas aeruginosa/isolation & purification
7.
Braz J Infect Dis ; 2(1): 25-30, 1998 Feb.
Article in English | MEDLINE | ID: mdl-11101908

ABSTRACT

Cefprozil is a new oral second generation cephalosporin. Its in vitro antimicrobial activity was evaluated against 371 recent clinical isolates from patients with respiratory infections. We tested the susceptibility of 244 streptococci (96 Streptococcus pneumoniae, 105 group viridans streptococci, 32 Streptococcus agalactiae, and 11 group A beta-hemolitic streptococci) 107 Haemophilus influenzae, and 20 oxacillin-susceptible S.aureus (OSSA). The isolates were susceptibility tested against cefprozil, cefaclor and amoxicillin/clavulanic acid by the E-test method; and against cefadroxil, cefuroxime, cefetamet, erythromycin, and azythromycin by disk diffusion. The methods and the susceptibility categorization followed the National Committee for Clinical Laboratory Standards (NCCLS) procedures. Amoxicillin/clavulanic acid was slightly more active againstH.influenzae (MICs(90) 0.5µg/mL) than cefprozil or cefaclor (MICs(90) 4 and 2µg/mL respectively). Cefprozil demonstrated potent activity against streptococci. Against S.pneumoniae, cefprozil was 2-4 fold more active than cefaclor (MICs(90)0.125 and 0.38µg/mL, respectively). S. pneumoniae susceptibility was 84% to penicillin, 95% to erythromycin and 97% to azithromycin by disk diffusion. Viridans streptococci showed higher MICs for cefprozil and cefaclor (MICs(90) 4µg/mL and 8µg/mL, respectively) and only 50% susceptibility to the macrolides. Cefprozil was four times more active than cefaclor and as active as amoxieillin/clavulanic acid against group A beta-hemolytic streptococci and S.agalactiae. These three compounds showed similar activity against OSSA. In conclusion, cefprozil demonstrated excellent in vitro activity against bacterial species responsible for respiratory infections in São Paulo.

8.
Braz J Infect Dis ; 1(6): 294-305, 1997 Dec.
Article in English | MEDLINE | ID: mdl-11105151

ABSTRACT

Meropenem is a parenteral carbapenem antibacterial agent with a very broad spectrum of antibacterial activity. It is the second agent of its class to become available in Brazil. The in vitro antibacterial activity of meropenem was compared with imipenem and four other antimicrobial agents in a multicenter study. This study involved 13 clinical microbiology laboratories, 10 of which came from 8 Brazilian states. A total of 2,085 clinical isolates consecutively collected between December 1995 and March 1996 were susceptibility tested using the Etest and following the NCCLS procedures. Meropenem inhibited more than 90% of isolates of Enterobacteriaceae at 0.5 µg/mL, except for Citrobacter sp. (1 µg/ml). Generally, meropenem was slightly more active than imipenem against Gram-negative organisms and its spectrum of antimicrobial activity was broader than those of all other drugs tested. Against Pseudomonas aeruginosa, meropenem (MIC50, 0.38 µg/ml) was approximately 8-fold more active than imipenem (MIC 50,3 µg/mL). Imipenem was two-to eight-fold more active than meropenem against some Gram-positive specees oxacillin, including Enterococcus faecalis (MIC 50 of 0.75 µg/mL and 2 µg/mL respectively), oxacillin-susceptible Staphylococcus aureus (MIC 50 of 0.47 &mul;g/mL and 0.094 µg/mL), oxacillin-susceptible Staphylococcus epidermidis (MIC 50 of 0.064 µg/mL and 0.5mg/mL). Against Streptococcus sp. meropenem was slightly more active than imipenem (MIC 50, 0.016 µg/mL). The results of this study may be used to guide empiric therapy in Brazil and indicates that meropenem may have an important role in the treatment of infections caused by multiresistant strains of bacteria.

9.
Rev. Assoc. Med. Bras. (1992, Impr.) ; 42(3): 147-50, jul.-set. 1996. tab
Article in Portuguese | LILACS | ID: lil-186298

ABSTRACT

Objetivo. Avaliar a sensibilidade de Enterococcus e Staphylococcus à teicoplanina e à vancomicina. Métodos. Foram estudadas 150 cepas de Enterococcus e 450 de Staphylococcus (298 Staphylococcus aureus e 152 de coagulase negativas) isoladas de três hospitais brasileiros. As CIMs foram determinadas utilizando o E Test. A concentraçao de antimicrobiano em cada fita foi de 256mcg/mL a 0,016mcg/mL. Também foi feito o estudo da sensibilidade pelo método de difusao empregando discos impregnados com 10mcg de teicoplanina e 30 mcg de vancomicina, respectivamente. Resultados. Todas as 298 cepas de Staphylococcus aureus foram sensíveis a dois antimicrobianos. Três cepas coagulase negativas apresentaram sensibilidade intermediária à teicoplanina (CIMs entre 8 e 16mcg/mL). Quatro das 150 cepas de Enterococcus apresentaram sensibilidade intermediária à vancomicina, mas foram totalmente sensíveis à teicoplanina. Conclusao. De acordo a estes resultados, teicoplanina e vancomicina sao boas opçoes terapêuticas nas infecçoes provocadas por Enterococcus e Staphylococcus.


Subject(s)
Staphylococcus/drug effects , Vancomycin/pharmacology , Enterococcus/drug effects , Teicoplanin/pharmacology , Microbial Sensitivity Tests
10.
Rev Assoc Med Bras (1992) ; 42(3): 147-50, 1996.
Article in Portuguese | MEDLINE | ID: mdl-9138356

ABSTRACT

PURPOSE: The study was performed in order to evaluate the susceptibility of Enterococcus and Staphylococcus to teicoplanin and vancomycin. METHODS: 150 Enterococcus strains and 450 Staphylococcus strains (298 Staphylococcus aureus and 152 negative coagulase strains) isolated in three Brazilian hospitals were studied. The MICs were determined using teicoplanin and vancomycin E Test strips. The range of the antimicrobial concentration in each strip went from 256 mcg/mL to 0.016 mcg/mL. Diffusion tests using disks impregnated with 10 mcg of teicoplanin and 30 mcg of vancomycin were also performed. RESULTS: All the 298 Staphylococcus aureus strains were susceptible to the two antimicrobials. Three of the 152 negative coagulase strains presented intermediate susceptibility to teicoplanin (MICs between 8 and 16 mcg/mL). Four of the 150 Enterococcus strains presented intermediate susceptibility to vancomycin but were totally susceptible to teicoplanin. CONCLUSION: According to these results teicoplanin and vancomycin are good therapeutical options in the treatment of staphylococcal and enterococcal infections.


Subject(s)
Anti-Bacterial Agents/pharmacology , Enterococcus/drug effects , Staphylococcus/drug effects , Teicoplanin/pharmacology , Vancomycin/pharmacology , Microbial Sensitivity Tests
SELECTION OF CITATIONS
SEARCH DETAIL
...